|
Mar 13
|
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|
|
Mar 13
|
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
|
|
Mar 12
|
Roche, Zealand sign deal: What it means for weight loss drug space
|
|
Mar 12
|
Novo Nordisk Is Falling. Competition Is a Killer.
|
|
Mar 12
|
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
|
|
Mar 12
|
Novo Nordisk, Starbucks shares slumping: Trending Tickers
|
|
Mar 12
|
iRobot, Target, Novo Nordisk vs. Roche: Market Minute
|
|
Mar 12
|
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
|
|
Mar 12
|
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
|
|
Mar 12
|
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal
|
|
Mar 12
|
Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com
|
|
Mar 12
|
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
|
|
Mar 12
|
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
|
|
Mar 12
|
Roche broadens obesity drug plans with $1.65B Zealand deal
|
|
Mar 12
|
Zealand and Roche strike $5.3bn obesity treatment deal
|
|
Mar 12
|
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
|
|
Mar 3
|
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
|
|
Mar 2
|
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
|
|
Feb 28
|
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
|